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Genomics and ELSI research
With the announcement of the Human Genome Project 
came speculation about a host of profound social 
challenges. Indeed, few areas of scientifi c inquiry have 
been subject to as much ethical scrutiny as genetics, and 
no scientifi c program has so systematically fostered the 
study of ethical, legal and social implications (ELSI) in 
parallel. Th is ELSI literature has led to a great deal of 
public debate, policymaking and the enactment of 
national legislation (for example, [1,2]) and international 
declarations [3]. But what does the available evidence tell 
us about the relevant social harms? Is the fi eld of 
genomics really causing social issues worthy of a formal 
policy response? In fact, the ethical, legal and social 
harms associated with genetics and genomics - be they in 
relation to patients, research participants, the research 
community or society more broadly - have turned out to 
be less certain and often less severe than originally 
anticipated, a point often neglected in public debates 
about genetic policy.
Emerging empirical evidence, which has been gathered 
by ELSI researchers throughout the world, has shed new 
light on many of the social challenges associated with 
genomics, including three of the most common areas of 
concern: the impact of gene patents, genetic discri mi-
nation, and testing-induced harm. For these areas  - 
which, of course, merely serve as examples of the many 
ELSI topics associated with genomic research - there are 
data that tell us that some harms exist. And these issues 
should not be ignored. But, as with the science of 
genomics, ELSI research reveals a more complex situa-
tion that is less amenable to defi nitive conclusions than 
often portrayed. As highlighted below, the available 
evidence  - that is, the evidence that is the result of an 
academic research study and not mere anecdote - tells us 
that the speculated harms have not, in general, 
materialized to the degree often suggested in the realm of 
popular discourse (for examples of such discourse see 
Table 1).
Despite this reality, many policy choices have been 
made, such as the enactment of legislation to curb 
discrimination and, in some jurisdictions, bans on public 
access to genetic tests. It seems that these policy moves 
have been based not on empirical evidence, but more on 
anecdote and speculation of possible harm. Although a 
quest for evidence cannot always be allowed to delay 
policy choice, policy options are surely the better for 
incorporating evidence when it exists. And when no data 
exist, ELSI research programs can sometimes fund 
projects to fi ll data gaps. Th is has important implications 
for public debates, policy development and the future of 
ELSI research. Future genomic policy should, as much as 
politically practical, be informed by and responsive to the 
relevant ELSI evidence.
ELSI examples
Genetic patents
Patents on human gene sequences have been contro-
versial from the start [4]. Although patent litigation, until 
recently, has centered mostly on gene patents for 
therapeutic proteins, such as insulin, growth hormone, 
and erythropoietin [5], most of the controversy has 
instead centered on concerns that gene patents might 
encumber clinical access to genetic testing and impede 
clinical and basic research. Indeed, as noted in Table 1, 
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some commentators, such as author Michael Crichton, 
have gone so far as to suggest that gene patents may lead 
to unjustified deaths.
But what does the evidence actually say? Although 
early and relatively small studies suggested that patents 
and exclusive licensing reduced availability of genetic 
testing [6,7], recent empirical analysis has found little 
evidence that patents substantially or pervasively hinder 
provision of clinical genetic testing [8-11]. Evidence is 
also ambiguous about patent effects on test prices [8], 
basic research and the degree to which patents have 
created incentives for genetic test development for the 
majority of Mendelian genetic disorders. Data on whether, 
and to what extent, patents may foster or hinder 
development of promising new clinical technologies, 
such as highly parallel multigene tests and clinical whole-
genome/exome sequencing, are only just emerging [12] 
and are in no way conclusive. A shadow of uncertainty 
due to patent infringement liability hovers over whole-
genome/exome sequencing tests, but initial empirical 
work suggests that there may be greater freedom to 
operate than perceived [13,14].
Despite the equivocal nature of the evidence, contro-
versy persists, as highlighted by ongoing litigation over 
the patents filed by Myriad Genetics, Inc. (Salt Lake City, 
Utah, USA) on the BRCA1 and BRCA2 breast cancer 
genes in the US and a parallel case in Australia. Indeed, 
the US litigation, sponsored by the American Civil 
Liberties Union and Public Patent Foundation [15], has 
become by far the most conspicuous gene patent case in 
history. BRCA patents have already been the subject of 
intense policy debate in Europe, Australia and Canada. 
The case has generated intense media attention, which, 
like previous media discourse about BRCA gene patents 
[16], has been decidedly negative  - probably partly as a 
result of Myriad’s business practices, which have 
alienated physicians, researchers and patients. This high-
profile case created a narrative that seems to support the 
social concerns so often associated with patents. But, in 
reality, this case stands as an example of the power of an 
anecdote or outlier case rather than definitive proof of 
systemic problems [17].
In total, the available evidence tells us that the alleged 
harms (and, for that matter, the suggested benefits) of 
human gene patenting have been overstated and over-
simplified. Studies, in fact, reveal a more nuanced picture.
Testing-induced harm
One of the core concerns associated with the emergence 
of genetic testing technologies  - particularly in the 
context of direct-to-consumer (DTC) testing - is that the 
information on genetic risk will cause harm. With the 
Table 1. Examples of public discourse on ELSI
 Quote Source
Patents “The AMA [American Medical Association] is opposed to gene patenting because 
it has the potential to inhibit access to genetic testing for patients and hinder 
research on genetic disease.”
American Medical Association website 
[45]
“[W]e believe [gene patenting] may potentially…[l]ead to significant limitations 
in genetic research…[s]tifle the development of innovative tests … and [c]reate 
exorbitant licensure costs that will be passed on to the consumer.”
National Society of Genetic Counselors, 
2010 [46]
“It’s wrong to think that something as naturally occurring as DNA can be 
patented by a single company that limits scientific research and the free 
exchange of ideas...”
Chris Hansen, American Civil Liberties 
Union staff lawyer, in an interview with the 
Huffington Post, 2012 [47]
“You, or someone you love, may die because of a gene patent that should never 
have been granted in the first place.”
Michael Crichton, The New York Times, 
2007 [48]
Testing anxiety “Gene tests ‘create undue stress’” BBC News, 2008 [49]
“The emotional impact of positive test results can be significant and can cause 
persistent worry, confusion, anger, depression, and even despair.’’
US Secretary’s Advisory Committee on 
Genetic Testing, 2000 [19]
“Genetic testing can help patients make decisions if the information means 
something specific, but often, it doesn’t. In fact, these journeys often bring 
intense anxiety due to the uncertainty - what one researcher calls ‘toxic 
knowledge’.”
Ricki Lewis, Scientific American blog, 
2012 [50]
Genetic discrimination “Genetic discrimination affects us all! Who has perfect genes?” Canadian Coalition for Genetic Fairness 
website [51]
“Gene testing exposes us all to discrimination” Sydney Morning Herald, 2010 [52]
“Fear of misuse is already preventing people from undergoing genetic testing 
and participating in clinical trials that are needed to treat disease.”
Globe and Mail, 2012 [53]
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increasing public availability of a range of testing services, 
including tests for both relatively superficial traits such as 
athletic ability and those that disclose the risk of 
potentially serious diseases, many speculated that genetic 
test results could be misinterpreted, encourage unhealthy 
and fatalistic behavior, and cause anxiety and even 
depression [18,19]. The large numbers of unreliable genetic 
tests offered to the public on the Internet was also 
perceived as a potential threat to the efficient running of 
public healthcare systems. These concerns have been at 
the heart of calls for regulation and oversight [19,20].
So far, however, there is little evidence to support the 
idea that, in general, people have an adverse or unhealthy 
reaction to genetic risk information [21]. Although the 
data are still emerging and most commentators seem to 
agree that accurate advertising and testing is essential 
[22], the relevant studies have found little evidence of 
fatalism [22] or persistent increased anxiety [23]. Indeed, 
genetic risk information seems to have little long-term 
impact of any kind on perceptions or behavior [24,25]. Of 
course, this does not mean that there are no issues; 
certain individuals or groups may be more sensitive and, 
thus, more likely to react poorly to genetic ‘bad news’ or 
feel survivor guilt for ‘good news’ when others in their 
family have deleterious mutations. But the data do raise 
questions about the magnitude of the problem and the 
ways in which policy-makers might respond, which, so 
far, have included everything from outright bans on DTC 
testing to the suggestion (and in Germany, a national law) 
that genetic testing should only be provided by a licenced 
health professional [26].
Genetic discrimination
Reports predicting the emergence of a new genetic 
underclass who would be excluded from many aspects of 
social life (for example, unable to get life or health 
insurance, or being discriminated against in getting a job) 
have emerged steadily in scientific and popular media 
over the past 20 years [27,28]. As a result of these reports, 
genetic discrimination emerged as a dominant social 
concern leading to a range of policy responses. In Europe, 
concern over genetic discrimination has resulted in the 
adoption of a plethora of laws, guidelines and policies, 
both at the regional (Council of Europe, European Union) 
and national level [29]. In the US and the UK, and more 
recently Australia, legislators have felt compelled to 
adopt protective legal measures specifically addressing 
discrimination [30,31]. For example, in the US, the 
Genetic Information Nondiscrimination Act addressed 
health insurance and job discrimination, and provisions 
of the Health Insurance Portability and Accountability 
Act [32] and the Patient Protection and Affordable Care 
Act [33] also incorporated genetic nondiscrimination 
provisions.
Despite all this policy action, there is, in fact, little 
evidence suggesting that genetic discrimination is a signi-
ficant or common social phenomenon [34]. Some studies 
have suggested cases of genetic discrimination in the UK, 
North America and Australia, but important methodo-
logical limitations, contradictory results and the limited 
number of genetic conditions surveyed make it difficult 
to justify broad policy actions solely on the basis of this 
inconsistent empirical research [35]. At a minimum, it 
seems safe to conclude that the evidence of harm is not 
commensurate with the amount of policy attention the 
issue has received.
Of course, as with all of these areas, evidence of harm 
has rarely been the main driver of policy regarding 
genetic discrimination. Many factors have contributed to 
the push for regulatory reform, including a perceived 
need to quell public fears in order to ensure participation 
in research, media coverage of anecdotal events, social-
cultural and historical elements, and simply the absence 
of good reasons not to prevent discrimination on the 
basis of genetic factors that individuals cannot control. 
The latter two factors seem particularly relevant to 
continental Europe where, despite the almost complete 
lack of evidence, local governments have adopted robust 
laws and policies to address the perceived problem of 
genetic discrimination.
As with gene patents and genetic testing-induced harm, 
it would be misleading to suggest that the ubiqui tous 
policy activity in this domain has been informed by solid 
evidence of widespread harm. One notable excep tion is 
the case of Huntington’s disease, for which sub stantial data 
about the negative treatment of carriers has been gathered 
over the years [36]. However, because it is a well-known 
autosomal dominant condition, even in the absence of 
genetic tests, discrimination would probably still be 
possible  - and, in the case of life insurance, not without 
technical justification - on the basis of family history.
ELSI hype?
The nature and magnitude of ELSI concerns are closely 
tied to the relevant scientific developments. Given that 
the conclusions of genetic research have proven to be less 
definitive than previously anticipated, it should be no 
surprise that the same trend is found in the context of 
ELSI. Many of these issues, including those discussed 
above, flow from assumptions about the predictive power 
of genetic information. Although it is certainly true that 
some genetic risk information is highly predictive, we 
now know that is not the case for most forms of genetic 
information, particularly regarding common, chronic 
diseases [37-39].
The slow march of clinical adoption of genomic tech-
nologies could, in part, explain the conclusions found in 
the relevant ELSI research. If genetic information is not, 
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in general, highly predictive, then the value of gene 
patents is low except in unusual cases, and there is no 
reason for individuals to become overly anxious or 
fatalistic when faced with genetic test results. It thus 
seems a dubious cause of institutionalized discrimination; 
in fact, evidence on genetic discrimination is generally 
limited to a handful of classic, highly familial, genetic 
conditions [35].
Nevertheless, policymakers and public discourse often 
seem wedded to old views of social harm (Table 1)  - 
views that are not necessarily supported by empirical 
data. To be clear, we are not saying that all policy action 
must be founded on empirical evidence alone. Concep-
tual analysis and the desire to protect rights and well-
established ethical norms must and can support a range 
of policy responses. But when the call for reform is based 
on the existence of testable harms - as is the case with the 
issues outlined above  - it seems axiomatic that the 
relevant evidence should guide policy action.
The persistence of these concerns is the result of a wide 
range of complex forces, including the fact that they may 
be proxies for general social angst about the impact of 
science on society. Likewise, they may fit with preexisting 
social values or help to promote a related policy agenda 
(for example, the concern about gene patents fits well 
with the concern about the commercialization of science 
and health systems). Finally, it is worth considering the 
role of the ELSI community itself. Just as with the 
inappropriate ‘hype’ that has often been associated with 
the field of genomics [40], there may be a degree of ‘ELSI 
hype’  - that is, a possible (and probably inadvertent) 
exaggerated portrayal of harm and the need for policy 
reform. Although further research on the existence of 
this phenomenon is required, the drivers of ELSI hype 
probably include the biases of scholars, their needs to 
obtain research funds, media interest in portraying social 
concerns as immediate and acute, and polarized public 
debates.
Conclusions
Some of the untoward effects so often associated with the 
‘genomic revolution’ are less scary than expected. Part of 
the reason for this reality, at least in part, could be the 
fact that the ELSI community has been watching and 
writing about ELSI and fostering a broad public debate. 
But in many respects, the postulated genomic cataclysm 
is really a story of the dog that did not bite. There is little 
evidence, for example, to support the idea that gene 
patents are having an adverse impact on the research 
environment, that genetic testing causes long-term 
anxiety, or that genetic discrimination is a common 
phenomenon. All of these conclusions  - and there is, of 
course, similar research in other domains of genetics  - 
should shape the direction of policy in these areas.
It would be easy to take our observations as an 
invitation to inaction, and to argue that ELSI studies have 
been a waste of money and time because evidence of 
wide spread harm has failed to materialize. On the 
contrary, we argue that ELSI research programs through-
out the world have created a healthy culture of skeptical 
scrutiny, a salutary result for deliberative democracies. 
Indeed, the ELSI model seems worth emulating  - with 
deliberative commissions and academic ELSI scholarship 
progressing in parallel with scientific and technical 
advances, not only for genomics but also other fields (for 
example, the field of stem cell research often integrates 
ELSI work). The story could have unfolded through 
gathering evidence of harm and presenting it to policy 
makers to rectify problems. In fact, however, it has been 
much more a tale of ongoing public debate, active 
outreach to concerned constituencies in part based on 
ELSI scholarship, and policy change intended to forestall 
problems before they occur, or as cases arise. So far in the 
context of genetics, policy change has not generally been 
driven by evidence and facts, but rather by debate and 
foresight based on plausible arguments. But when 
evidence is available  - a direct result of the significant 
commitment to ELSI scholarship  - the relevant data 
should not be ignored. In an era that is striving to 
embrace evidence-based policy, empirically derived data 
on the nature and scope of harms should, in general, take 
precedence over anecdote. If good data exist, they should 
be cited in policy debates; if data do not exist, then 
research should be funded to supply them.
New policy decisions loom on the horizon, such as the 
push for policies to address whole-genome analysis 
technologies [41] (including the recommendation of laws 
that would grant individuals exclusive and enduring 
property rights over their genetic information [42,43]) 
and the continuing concerns about DTC testing [44]. 
And, of course, the debates about gene patents seem 
likely to continue even after the US Supreme Court hands 
down its decision on Myriad Genetics. We hope that 
these policies will also be informed by past and emerging 
ELSI work. This will require, inter alia, engaging relevant 
policy makers, making ELSI work accessible, taking steps 
to avoid ‘ELSI hype’ and, going forward, ensuring that 
future ELSI research is responsive to the policy-making 
community.
Systematic cultivation of ELSI research was an 
innovation in the new field of genomics in the late 1980s. 
It should not be chided because it did not save the world 
from catastrophe. The story is less heroism in the face of 
adversity than prudence in the face of uncertainty. But 
policy action should not be founded solely on either 
speculation or amorphous social angst. We must embrace 
what the ELSI research tells us. To do otherwise would 
run counter to the idea of evidence-based policy.
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